Advertisement
Nationwide database study finds racial and regional variations
Findings offer reassurance, clarify understanding of cardiorenal syndrome
Insights on the PROTECTED TAVR and WATCH-TAVR trials
Cohort study provides insights on TAVR in an understudied group
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Pooled results of 11 observational studies offer needed guidance on PCI in this setting
30-day risk assessed among 100,000+ TAVR patients in U.S.
PARTNER 3 and CoreValve Low Risk reveal pros and cons of both approaches
Surprisingly, biggest effect seen in patients with preserved LVEF
Expanding indications, device refinements and accessory treatments
Experts weigh in on proposed changes to reimbursement requirements
Advertisement
Advertisement